4 February 2025 LSIPR sister title WIPR releases USA Patents Rankings, divided into categories of non-contentious and ...

Disputed drug forms part of a multi-billion dollar franchise for J&J, ranking among its largest revenue drivers in mental ...

For startups, getting a drug to market is a marathon but founders need to think beyond filing patents to win over investors, ...

LSPN panellists from Mathys & Squire discuss recent developments affecting the EPO Boards of Appeal and decisions emerging ...

California medical device company sues rival at the ITC and in Delaware court over “copycat” brain monitoring system launch in May | Ceribell accuses competitor of “a history of willful patent ...

German and Finnish pharma giants sue Indian rival in Delaware court | Dispute centres on generic bid for prostate cancer ...

Office declined application, citing earlier authorisations for inhalers designed for people containing the same ingredient | Boehringer argued that ciclesonide was a ‘new active substance’ not ...

New addition expected to strengthen firm’s foundational ‘IP’ practice. If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, ...

The architect of an historic change in the way patent claims are interpreted explains what it means for AI drafting, and why more harmonisation may follow, reports Tom Phillips.

Board of Appeal upholds opposition challenge over added subject-matter claims | Dispute concerned patent relating to T cell therapeutic manufacturing methods.